Today's Dead Cat Bounce Stock Is Anacor Pharmaceuticals (ANAC)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Anacor Pharmaceuticals ( ANAC) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Anacor Pharmaceuticals as such a stock due to the following factors:

  • ANAC has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $42.7 million.
  • ANAC has traded 51,396 shares today.
  • ANAC is up 3% today.
  • ANAC was down 5.1% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ANAC with the Ticky from Trade-Ideas. See the FREE profile for ANAC NOW at Trade-Ideas

More details on ANAC:

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. Currently there are 4 analysts that rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Anacor Pharmaceuticals has been 648,700 shares per day over the past 30 days. Anacor has a market cap of $2.4 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.78 and a short float of 13.9% with 5.79 days to cover. Shares are up 69.6% year-to-date as of the close of trading on Wednesday.

If you liked this article you might like

Lack of Catalysts Keeps Analysts Away From Pfizer

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

Allergan's Dealmaking Continues With Vitae Takeout

Will Pfizer Book Another Healthy Quarter?

Ardelyx Has Big Potential

Ardelyx Has Big Potential